{"id":51106,"date":"2022-11-21T23:02:24","date_gmt":"2022-11-21T22:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/"},"modified":"2022-11-21T23:02:24","modified_gmt":"2022-11-21T22:02:24","slug":"amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/","title":{"rendered":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes"},"content":{"rendered":"
\n

OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces that it will begin dispensing TZIELD\u2122 (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two or more T1D-related autoantibodies and abnormal blood sugars. TZIELD\u2122 is manufactured by Provention Bio, Inc., a New Jersey-based biopharma company.\n<\/p>\n

\nAmber Specialty Pharmacy\u2019s high touch, infusion-focused service model is designed to support provider offices and appropriate patients with Stage 2 T1D across the country who may be prescribed teplizumab. The specialty pharmacy has 19 locations ready to care for these patients with their comprehensive services as well as ambulatory and home infusion capabilities.\n<\/p>\n

\n\u201cLiving with or caring for a child with T1D requires constant daily management,\u201d said Kristin Williams, president of Amber Specialty Pharmacy. \u201cWe understand how important it is for at-risk individuals to have access to medication and reliable support in order to delay disease progression. We are honored Provention Bio recognizes our passion for patients and infusion program capabilities to care for this population with their first-of-its-kind treatment option.\u201d\n<\/p>\n

\nFor more information about Amber Specialty Pharmacy services, call (888) 370-1724 or visit www.amberpharmacy.com<\/a>. Read more about the pharmacy\u2019s infusion service offerings here.<\/a>\n<\/p>\n

\nAmber Specialty Pharmacy<\/b>, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with nearly 25 years of experience providing specialized care for persons with chronic, complex medical conditions. Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families. This comprehensive care approach supports the medical, emotional, financial and administrative needs of patients throughout the United States. Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 18 locations throughout the United States and Puerto Rico. Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDawn Buzynski
\n
Director, Strategic Communications
\n
(515) 695-3090\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces that it will begin dispensing TZIELD\u2122 (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51106","6":"format-standard","7":"category-industry"},"yoast_head":"\nAmber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces that it will begin dispensing TZIELD\u2122 (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T22:02:24+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes\",\"datePublished\":\"2022-11-21T22:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/\",\"name\":\"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-21T22:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/","og_locale":"en_US","og_type":"article","og_title":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend","og_description":"OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces that it will begin dispensing TZIELD\u2122 (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T22:02:24+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes","datePublished":"2022-11-21T22:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/"},"wordCount":387,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/","url":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/","name":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-21T22:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/amber-specialty-pharmacy-selected-to-dispense-tzield-teplizumab-a-monoclonal-antibody-treatment-to-delay-onset-of-stage-3-type-1-diabetes-in-patients-ages-8-years-and-older-with-stage-2-ty\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Amber Specialty Pharmacy Selected to Dispense TZIELD\u2122 (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51106"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51106\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}